Rani Therapeutics Holdings, Inc. Class A Common Stock (RANI)

Price$0.83

Value ScoreD

Growth ScoreA

Momentum ScoreD

Favorite Metrics

Price vs S&P 500 (26W)-56.08%

Price vs S&P 500 (4W)-14.08%

VGM Score49.92

Market Capitalization$102.76M

All Metrics

Book Value / Share (Quarterly)$0.23

P/TBV (Annual)2.73x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)-15.64%

Cash Flow / Share (Quarterly)$-0.14

Price vs S&P 500 (YTD)-46.71%

Net Profit Margin (TTM)-547.11%

EPS (TTM)$-0.41

10-Day Avg Trading Volume1.14M

EPS Excl Extra (TTM)$-0.41

Revenue Growth (5Y)10.75%

EPS (Annual)$-0.45

ROI (Annual)-89.89%

Net Profit Margin (5Y Avg)-2277.42%

Cash / Share (Quarterly)$0.35

Revenue Growth QoQ (YoY)893.02%

ROA (Last FY)-50.62%

Revenue Growth TTM (YoY)164.08%

EBITD / Share (TTM)$-0.33

ROE (5Y Avg)-392.26%

Operating Margin (TTM)-550.65%

Cash Flow / Share (Annual)$-0.15

P/B Ratio3.62x

P/B Ratio (Quarterly)3.20x

Net Income / Employee (Annual)$-430,000

EV / Revenue (TTM)29.38x

Net Interest Coverage (TTM)-18.84x

ROA (TTM)-85.63%

EPS Incl Extra (Annual)$-0.45

Current Ratio (Annual)4.21x

Quick Ratio (Quarterly)3.30x

3-Month Avg Trading Volume1.08M

52-Week Price Return56.81%

Revenue / Employee (TTM)$45,900

Tangible BV / Share (Quarterly)$0.35

P/S Ratio (Annual)62.93x

Asset Turnover (Annual)0.03x

52-Week High$3.87

Operating Margin (5Y Avg)-3169.63%

EPS Excl Extra (Annual)$-0.45

CapEx CAGR (5Y)-40.70%

26-Week Price Return-48.16%

Quick Ratio (Annual)4.08x

13-Week Price Return-38.10%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)3.40x

Enterprise Value$93.12M

Revenue / Share Growth (5Y)3.90%

Asset Turnover (TTM)0.06x

Revenue / Employee (Annual)$23,700

Pretax Margin (Annual)-2507.65%

Cash / Share (Annual)$0.41

3-Month Return Std Dev107.13%

Net Income / Employee (TTM)$-426,700

ROE (Last FY)-89.89%

Net Interest Coverage (Annual)-15.61x

EPS Basic Excl Extra (Annual)$-0.45

Receivables Turnover (TTM)2.40x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-0.41

ROI (TTM)-56.46%

P/S Ratio (TTM)32.43x

Pretax Margin (5Y Avg)-3259.90%

Revenue / Share (Annual)$0.02

Tangible BV / Share (Annual)$0.75

Price vs S&P 500 (52W)32.44%

Year-to-Date Return-38.56%

5-Day Price Return-7.39%

EPS Normalized (Annual)$-0.45

ROA (5Y Avg)-45.25%

Net Profit Margin (Annual)-1817.09%

Month-to-Date Return-12.76%

Cash Flow / Share (TTM)$-2.79

EBITD / Share (Annual)$-0.57

Operating Margin (Annual)-2381.26%

LT Debt / Equity (Annual)0.00x

ROI (5Y Avg)-69.41%

LT Debt / Equity (Quarterly)0.00x

EPS Basic Excl Extra (TTM)$-0.41

P/TBV (Quarterly)5.73x

P/B Ratio (Annual)4.97x

Pretax Margin (TTM)-539.26%

Book Value / Share (Annual)$0.27

Price vs S&P 500 (13W)-46.35%

Beta0.86x

Revenue / Share (TTM)$0.02

ROE (TTM)-56.46%

52-Week Low$0.39

vGradeD

gGradeA

mGradeD

vgmGradeC

Show chart for

Earnings Surprise History

Q1 26-0.04est. -0.05

Analyst Recommendations

Feb 2026

Mar 2026

Apr 2026

May 2026

4.11

4.10

Industry Peers — Pharmaceuticals(550)

Symbol	Value Score	Growth Score	Momentum Score	Price
RANIRani Therapeutics Holdings, Inc. Class A Common Stock	D	A	D	$0.83
LLYEli Lilly & Co.	D	B	B	$1131.42
JNJJohnson & Johnson	D	C	B	$232.77
ABBVABBVIE INC.	D	C	C	$227.23
MRKMerck & Co., Inc.	C	C	B	$120.79
NVSNovartis AG	C	C	C	$149.16
AZNAstraZeneca PLC	D	B	C	$185.95
NVONovo-Nordisk A/S	B	B	B	$42.96
ABTAbbott Laboratories	C	C	D	$91.07
PFEPfizer Inc.	B	C	C	$26.04
BMYBristol-Myers Squibb Co.	B	C	B	$57.27

About

Rani Therapeutics is a clinical-stage biotherapeutics company developing the RaniPill platform to deliver biologics such as antibodies, proteins, peptides, and oligonucleotides orally instead of by injection. The proprietary technology aims to provide patients and healthcare systems with a more convenient alternative to painful subcutaneous or intravenous injections. The company is also advancing RaniPill HC to enable delivery of liquid drug payloads with high bioavailability.